What is Aldeyra Therapeutics Profitability Rank?
Aldeyra Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Aldeyra Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Aldeyra Therapeutics's Piotroski F-Score is 2.
Competitive Comparison of Aldeyra Therapeutics's Profitability Rank
For the Biotechnology subindustry, Aldeyra Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Profitability Rank falls into.
Aldeyra Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Aldeyra Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Aldeyra Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Aldeyra Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Aldeyra Therapeutics (Aldeyra Therapeutics) Business Description
Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Executives
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Todd C Brady |
director, officer: President and CEO |
C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075 |
| Martin Joseph Joyce |
director |
1050 HINGHAM STREET, ROCKLAND MA 02370 |
| Bruce Greenberg |
officer: See Remarks |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Stephen Machatha |
officer: Chief Development Officer |
131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Richard Douglas |
director |
ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
| Nancy Miller-rich |
director |
C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
| Ben Bronstein |
director |
15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
| David J Clark |
officer: Chief Medical Officer |
131 HARTWELL AVE, LEXINGTON MA 02421 |
| David Mcmullin |
officer: SVP Corp. Dev. & Strategy |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Joshua Reed |
officer: Chief Financial Officer |
C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
| Jesse I Treu |
director, 10 percent owner |
|
| Stephen J Tulipano |
officer: Chief Financial Officer |
C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALDX has been successfully added to your